CagriSema: Semaglutide + Amylin Combination Drug

When Eli Lilly's tirzepatide demonstrated superior weight loss compared to semaglutide, Novo Nordisk needed a response. That response is CagriSema — a combination that pairs their proven semaglutide with cagrilintide, targeting a completely different hormonal pathway. Early results suggest this combination could produce weight loss of 22-25% or more, making it one of the most promising obesity drugs in development.

Understanding Amylin: The Missing Piece

To understand why CagriSema represents a meaningful advance, you need to understand amylin — a hormone that has been largely overlooked in the weight loss medication landscape until recently.

What Is Amylin?

Amylin (also called islet amyloid polypeptide, or IAPP) is a hormone produced by the beta cells of the pancreas — the same cells that produce insulin. When you eat, amylin is co-secreted alongside insulin and performs several important functions:

• Slows gastric emptying: Like GLP-1, amylin delays how quickly food leaves your stomach, promoting prolonged satiety
• Suppresses glucagon: Amylin reduces the release of glucagon after meals, helping prevent post-meal blood sugar spikes
• Promotes satiety: Amylin acts on the area postrema and other brain regions to signal fullness, using a different neural pathway than GLP-1
• Reduces food intake: Through its brain effects, amylin reduces meal size and food intake

Why Combine Amylin with GLP-1?

GLP-1 and amylin regulate appetite through different but complementary pathways. GLP-1 primarily acts through the hypothalamus and reward centers, while amylin works through the area postrema and hindbrain. Activating both systems simultaneously produces greater appetite suppression and weight loss than either alone — a concept known as additive or synergistic pharmacology.

Think of it like this: GLP-1 turns down the volume on hunger signals and food cravings in one part of your brain, while amylin turns down the volume in another part. Together, they quiet hunger more effectively than either could alone.

What Is Cagrilintide?

Cagrilintide is Novo Nordisk's long-acting amylin analog — a synthetic version of amylin that has been modified to last much longer in the body. While natural amylin has a half-life of only about 15-20 minutes, cagrilintide persists for approximately one week, enabling once-weekly dosing.

Pramlintide (brand name Symlin) was the first amylin analog approved by the FDA (in 2005, for diabetes), but it required three-times-daily injections and produced modest weight loss. Cagrilintide's long-acting design overcomes these limitations and delivers more potent effects.

Clinical Trial Results

Phase 2 Data

The Phase 2 trial tested CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) against each component individually and placebo in adults with obesity over 32 weeks:

Phase 3: The REDEFINE Program

The Phase 3 REDEFINE clinical trial program is testing CagriSema across multiple patient populations:

• REDEFINE 1: Adults with obesity or overweight without diabetes (68 weeks)
• REDEFINE 2: Adults with type 2 diabetes and obesity
• REDEFINE 3: Long-term cardiovascular outcomes study
• REDEFINE 4: Head-to-head comparison with tirzepatide
• Additional trials in specific populations including knee osteoarthritis and heart failure

Early Phase 3 results from REDEFINE 1 have shown average weight loss in the range of 22-25% over 68 weeks, positioning CagriSema as a serious competitor to tirzepatide for the most effective injectable weight loss medication.

CagriSema vs Tirzepatide: The Rivalry

The competition between CagriSema and tirzepatide (Zepbound) represents one of the most significant rivalries in pharmaceutical history. Both approaches produce similar weight loss, but through different mechanisms:

The REDEFINE 4 trial, which directly compares CagriSema against tirzepatide, will provide the clearest picture of how these two approaches stack up against each other. This head-to-head data will be invaluable for clinicians and patients choosing between options.

What CagriSema Means for Patients

For patients currently using or considering GLP-1 medications, CagriSema represents:

• More options: Having multiple highly effective medications allows for personalized treatment selection based on individual response, tolerability, and insurance coverage
• Competitive pressure on pricing: Competition between Novo Nordisk and Eli Lilly may help drive down costs over time
• An upgrade path: Patients currently on semaglutide who want more weight loss could potentially switch to CagriSema without changing their GLP-1 component
• Complementary mechanism: For patients who plateau on GLP-1-only therapy, adding amylin stimulation through CagriSema could restart weight loss

For information about currently available treatments, visit our treatments page or learn how GLP-1 medications work.